Physician profile
Michael L Aaronson
NPI 1326014028
$498,418.78
in general payments reported to CMS, 2019-2025
34 companies · $102K in 2025
The $102K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.21 · 2020: $32.94 · 2021: $34K · 2022: $157K · 2023: $66K · 2024: $140K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $276K · Travel and Lodging: $11K · Honoraria: $7,347 · Food and Beverage: $6,674 · Consulting Fee: $6,480 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $275,522.87 |
| Travel and Lodging | $11,473.66 |
| Honoraria | $7,346.91 |
| Food and Beverage | $6,673.91 |
| Consulting Fee | $6,480.00 |
| Education | $162.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $137,580.72 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110,253.45 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $87,000.70 | 2022-2025 | Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $61,747.40 | 2020-2024 | Farxiga, Lokelma, Xigduo |
| Bayer Healthcare Pharmaceuticals INC. | $36,106.22 | 2021-2025 | |
| Novo Nordisk INC | $34,529.78 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Scpharmaceuticals INC. | $20,314.28 | 2024 | |
| Eli Lilly and Company | $5,280.00 | 2024-2025 | Jardiance |
| Amgen INC. | $3,824.08 | 2021-2024 | Tavneos |
| Fresenius USA Marketing, INC. | $250.97 | 2021-2025 | Crit-Line, Velphoro |
| Mallinckrodt Hospital Products INC. | $229.48 | 2021-2025 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $210.71 | 2022-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $120.70 | 2023-2024 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $108.25 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $101.58 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $81.79 | 2021-2023 | |
| Vantive US Healthcare LLC | $77.67 | 2025 | Renal - Pd |
| Bard Peripheral Vascular, INC. | $70.18 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $67.95 | 2023 | Inpefa |
| Baxter Healthcare | $67.02 | 2022-2024 | |
| Medtronic, INC. | $64.87 | 2024 | Symplicity G3 |
| Calliditas Therapeutics US INC. | $53.86 | 2022-2024 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $40.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $36.77 | 2022-2025 | Jynarque |
| Esperion Therapeutics, INC. | $32.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.49 | 2022 | |
| Heartflow, INC. | $24.40 | 2025 | |
| Cormedix INC. | $19.81 | 2024 | Defencath |
| Regeneron Healthcare Solutions, INC. | $19.57 | 2024 | Evkeeza |
| Ultragenyx Pharmaceutical INC. | $16.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.56 | 2023 | Ultomiris |
| Merck Sharp & Dohme LLC | $15.31 | 2024 | Verquvo |
| Allergan, INC. | $15.21 | 2019 | |
| Nxstage Medical, INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Aaronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.